China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the commercial launch of its sacituzumab tirumotecan (SKB264/MK-2870) in China, marking a significant milestone in the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have been previously treated with at least two kinds of systematic treatment, including at least one for an advanced or metastatic stage. The marketing approval for this innovative treatment was secured just last month.
First Domestically Developed ADC Fully Approved in China
Sacituzumab tirumotecan (SKB264/MK-2870), a TROP2-targeted antibody drug conjugate (ADC), represents a breakthrough in cancer therapeutics. It was the subject of a licensing deal between Merck, Sharp & Dohme (MSD) for territories outside Greater China in May 2022. This drug stands as the first home-grown ADC to receive full regulatory approval in China, indicating a new era in domestic pharmaceutical innovation and development.
Implications for Cancer Treatment and the Pharmaceutical Industry
The launch of sacituzumab tirumotecan by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd is expected to have a profound impact on the treatment landscape for TNBC. By offering a new treatment option for patients with limited therapeutic alternatives, this ADC has the potential to improve patient outcomes and enhance the standard of care. This advancement is also a testament to the growing capabilities of China’s pharmaceutical sector to develop and bring to market complex, targeted therapies.-Fineline Info & Tech
